Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism;Lights off? A melatonerg és szerotonerg szinergizmus neurobiológiai és farmakológiai aspektusai

Neuropsychopharmacologia Hungarica

Volumn 12, Issue 4, 2010, Pages 469-475

  Andriás, Sümegi ^a   Csilla, Somoskovi ^b  

^a Vas Megyei Markusovszky Kórház Nonprofit Zrt   (Hungary)

^b Pszichiátriai es Addiktológiai Centrum   (Hungary)

Author keywords

5 HT2C receptor; Agomelatine; Depression; Melatonin; Melatonin receptors

Indexed keywords

AGOMELATINE; MELATONIN;

CHRONOBIOLOGY; DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; NEUROBIOLOGY; REVIEW; SEROTONINERGIC SYSTEM;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; CIRCADIAN RHYTHM; DEPRESSION; DEPRESSIVE DISORDER; DRUG SYNERGISM; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; META-ANALYSIS AS TOPIC; RECEPTORS, MELATONIN; SEROTONIN; SLEEP DISORDERS, CIRCADIAN RHYTHM;

EID: 78651351412     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, Ayala Ar, Licinio J, Gold HK, Kling MA, Chrousos GP, Gold PW. Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications. The Journal of Clinical Endocrinology & Metabolism 90(5):2522-2530.
2. Banasr M, Soumier A, Hery M, Mocaër E, Daszuta A. Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis. Biol Psychiatry 2006;59:1087-1096. (Pubitemid 43849657)
3. Bánki MC. Agomelatin: az elsocombining double acute accent "melatoninerg" antidepreszszívum. Neuropsychopharmacologia Hungarica 2006, VIII/3; 105-112.
4. Barbiero VS, Zappettini S, Mocaer E, Gabriel C, Mallei A, Milanese M, Musazzi L, Bonanno G, Racagni G, Popoli M. The novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampus. European neuropsychopharmacology. - ISSN 0924-977X. - 17:Suppl. 4(2007 Oct 04), pp. S365-S365.
5. Bódizs R, Purebl G, Rihmer Z. Hangulat, hangulatingadozások és depresszió: a cirkadián ritmusok szerepe. Neuropsychopharmacologia Hungarica 2010. XII/1, 277-287.
6. Calabrese F, Pescara F, Racagni G, Mocaer E, Molteni R, Riva MA.Modulation of Arc and BDNF following acute and chronic administration of agomelatine in rats. European neuropsychopharmacology. - ISSN 0924-977X. - 17:Suppl. 4(2007), pp. S333-S334.
7. Cardinali DP, Pevet P, 1998. Basic aspects of melatonin action. Sleep Med. Rev. 2, 175-190.
8. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000;25:48-52. (Pubitemid 30143328)
9. Duman RS, Nakagawa S, Mahlberg J (2001). Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25: 836-844. (Pubitemid 34031890)
10. Fournier JC; DeRubeis RJ; Hollon SD. Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis. JAMA. 2010;303(1):47-53.
11. Fuller CA, Lydic R, Sulzman FM, et al. Circadian rhythm of body temperature persists after suprachiasmatic lesions in the squirrel monkey. Am J Physiol 1981;241(5):R385-R391. (Pubitemid 12248160)
12. Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends in Molecular Medicine, Vol 13, Issue 2, 54-63.
13. 1A receptors in the rat brain. Neuropharmacology 47 (2004) 515-526.
14. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004;45(2), 104-14. (Pubitemid 38625738)
15. Holmes MC, French KL, Seckl JR. Dysregulation of diurnal rhythms of serotonin 5-HT2C and corticosteroid receptor gene expression in the hippocampus with food restriction and glucocorticoids. J Neurosci 1997;17:4056-65.
16. Kálmán J, Kálmán S. A depresszió mint kronobiológiai betegség. Neuropsychopharmacologia Hungarica 2009, XI/2, 69-81.
17. Kennaway DJ, Moyer RW, Voultsios A, Varcoe TJ. Serotonin, excitatory amino acids and the photic control of melatonin rhythms and SCN c-FOS in the rat. Brain Res 2001;897:36-43. (Pubitemid 32244350)
18. Klein DC, Moore RY, Reppert SM. Suprachiasmatic nucleus: the mind's clock. New York: Oxford University Press; 1991.
19. Lerner AB, Case JD, Takahashi Y, Lee, TH, Mori N. Isolation of melatonin, a pineal factor that lightens melanocytes. J. Am. Chem. Soc. 1958. 80, 2587.
20. Lynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychological Medicine (2010), 40, 9-24.
21. 2C properties. European Neuropsychopharmacology - 2009; Vol. 19 Suppl 3, S441-S442.
22. Maronde E, Stehle JH. The mammalian pineal gland: known facts, unknown facets. Trends Endocrinol. Metab. 18, 142-149.
23. 1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res 2000;28:185-92.
24. McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacology & Therapeutics 114 (2007) 222-232. (Pubitemid 46561535)
25. McIntyre IM, Burrows GD, Norman TR. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatry 1988;24(1):108-12.
26. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-Hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 2003;306, 954-964.
27. Miller AH, Maletic V, Raison CL. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psychiatry 2009;65:732-741.
28. Montgomery SA. Why do we need new and better antidepressants? Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S1-S10.
29. Paizanis E, Lelievre V, Saurini F, et al. Effects of agomelatine and fluoxetine on hippocampal cell survival, glucocorticoid receptors, and BDNF expression in a model of depression. Eur Neuropyschopharmacol. 2008;18(Suppl 4):S316.
30. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJM, Zisapel N, Cardinali DP. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Progress in Neurobiology 85 (2008) 335-353.
31. Papp M, Gruca P, Boyer PA, Mocaer E, Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003. 28, 694-703.
32. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. (1995). Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine, 25, 1171-1180.
33. Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. Journal of Biological Rhythms 2003. 13, 39-51.
34. Reppert SM, Perlow MJ, Artman HG et al. The circadian rhythm of oxytocin in primate cerebrospinal fluid: effects of destruction of the suprachiasmatic nuclei. Brain Res 1984;307(1-2):384-7.
35. Reynolds CF, Kupler D. Sleep in depression. In: Williams RZ, Karacan I, Moore CA (Eds.), Sleep disorders, diagnosis and treatment. ©1988, John Wiley, New York, pp. 147-164.
36. San L, Arranz B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European Psychiatry 23 (2008) 396-402.
37. Soumier A, Lortet S, Masmejean F, Gabriel C, Mocaer E, Millan MJ, Daszuta A. Cellular and molecular mechanisms underlying increased adult hippocampal neurogenesis induced by agomelatine, Neuropsychopharmacology 34 (2009), pp. 2390-2403.
38. Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiatry Research 165 (2009) 201-214.
39. Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual Modulation for Improved Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology 2003;23(1) 78-86.
40. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006;20(12):981-92.